Warning: Undefined array key "rcommentid" in /customers/6/5/f/pcm.me/httpd.www/wp-content/plugins/wp-recaptcha/recaptcha.php on line 348 Warning: Undefined array key "rchash" in /customers/6/5/f/pcm.me/httpd.www/wp-content/plugins/wp-recaptcha/recaptcha.php on line 349

Astelin

®
(azelastine hydrochloride) Nasal Spray, 137 mcg

For Intranasal Use Only

DRUG DESCRIPTION

What are the possible side effects of azelastine nasal (Astelin, Astepro)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Stop using azelastine and call your doctor at once if you have any of these serious side effects:

  • bronchospasm (shortness of breath, tightness in chest, wheezing); or
  • fast or uneven heartbeats.

Less serious side effects may include:

  • a bitter taste in your…

Read All Potential Side Effects and See Pictures of Astelin »

Astelin® (azelastine hydrochloride) Nasal Spray, 137 micrograms (mcg), is an antihistamine formulated as a metered-spray solution for intranasal administration. Azelastine hydrochloride occurs as a white, almost odorless, crystalline powder with a bitter taste. It has a molecular weight of 418.37. It is sparingly soluble in water, methanol, and propylene glycol and slightly soluble in ethanol, octanol, and glycerine. It has a melting point of about 225°C and the pH of a saturated solution is between 5.0 and 5.4. Its chemical name is (±)-1-(2H)- phthalazinone,4-[(4-chlorophenyl) methyl]-2-(hexahydro-1- methyl-1H-azepin-4-yl)-, monohydrochloride. Its molecular formula is C22H24CIN3O•HCl with the following chemical structure:

 

Astelin® Nasal Spray contains 0.1% azelastine hydrochloride in an aqueous solution at pH 6.8 ± 0.3. It also contains benzalkonium chloride (125 mcg/mL), edetate disodium, hypromellose, citric acid, dibasic sodium phosphate, sodium chloride, and purified water.

After priming, each metered spray delivers a 0.137 mL mean volume containing 137 mcg of azelastine hydrochloride (equivalent to 125 mcg of azelastine base). The bottle can deliver 200 metered sprays

INDICATIONS

Astelin® Nasal Spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis such as rhinorrhea, sneezing, and nasal pruritus in adults and children 5 years and older, and for the treatment of the symptoms of vasomotor rhinitis, such as rhinorrhea, nasal congestion and postnasal drip in adults and children 12 years and older.

DOSAGE AND ADMINISTRATION

Seasonal Allergic Rhinitis

The recommended dose of Astelin® Nasal Spray in adults and children 12 years and older with seasonal allergic rhinitis is one or two sprays per nostril twice daily. The recommended dose of Astelin® Nasal Spray in children 5 years to 11 years of age is one spray per nostril twice daily.

Vasomotor Rhinitis

The recommended dose of Astelin® Nasal Spray in adults and children 12 years and older with vasomotor rhinitis is two sprays per nostril twice daily.

Before initial use, the delivery system should be primed with 4 sprays or until a fine mist appears. When 3 or more days have elapsed since the last use, the pump should be reprimed with 2 sprays or until a fine mist appears.

CAUTION: Avoid spraying in the eyes.

Directions for Use: Illustrated patient instructions for proper use accompany each package of Astelin® Nasal Spray.

HOW SUPPLIED

Astelin® (azelastine hydrochloride) Nasal Spray, 137 mcg, (NDC 0037-0241-30) is supplied as a package containing 200 metered sprays in a high-density polyethylene (HDPE) bottle fitted with a metered-dose spray pump unit. A leaflet of patient instructions is also provided. The spray pump unit consists of a nasal spray pump fitted with a blue safety clip and a blue plastic dust cover.

The Astelin® (azelastine hydrochloride) Nasal Spray, 137 mcg, bottle contains 30 mg (1 mg/mL) of azelastine hydrochloride. The bottle can deliver 200 metered sprays. Each spray delivers a mean of 0.137 mL solution containing 137 mcg of azelastine hydrochloride.

Storage: Store at controlled room temperature 20°-25°C (68°- 77°F). Protect from freezing

SIDE EFFECTS

Seasonal Allergic Rhinitis

Astelin® Nasal Spray Two Sprays Per Nostril Twice Daily

Adverse experience information for Astelin® Nasal Spray is derived from six well-controlled, 2-day to 8-week clinical studies which included 391 patients who received Astelin® Nasal Spray at a dose of 2 sprays per nostril twice daily. In placebo-controlled efficacy trials, the incidence of discontinuation due to adverse reactions in patients receiving Astelin® Nasal Spray was not different from vehicle placebo (2.2% vs 2.8%, respectively). In these clinical studies, adverse events that occurred more often in patients treated with Astelin® Nasal Spray versus vehicle placebo included bitter taste (19.7% vs. 0.6%), somnolence (11.5% vs. 5.4%), weight increase (2.0% vs. 0%), and myalgia (1.5% vs. 0%).

The following table contains adverse events that were reported with frequencies ≥ 2% in the Astelin® Nasal Spray 2 sprays per nostril twice daily treatment group and more frequently than placebo in short-term ( ≤ 2 days) and long-term (2-8 weeks) clinical trials.

ADVERSE EVENT

Astelin®
Nasal Spray
n = 391

Vehicle
Placebo
n = 353

Bitter Taste

19.7

0.6

Headache

14.8

12.7

Somnolence

11.5

5.4

Nasal Burning

4.1

1.7

Pharyngitis

3.8

2.8

Dry Mouth

2.8

1.7

Paroxysmal Sneezing

3.1

1.1

Nausea

2.8

1.1

Rhinitis

2.3

1.4

Fatigue

2.3

1.4

Dizziness

2.0

1.4

Epistaxis

2.0

1.4

Weight Increase

2.0

0.0

Astelin® Nasal Spray One Spray Per Nostril Twice Daily

Adverse experience information for Astelin® Nasal Spray at a dose of one spray per nostril twice daily is derived from two placebo-controlled 2-week clinical studies which included 276 patients. None of the patients receiving Astelin® Nasal Spray were discontinued from these studies due to adverse reactions. Three patients receiving vehicle placebo were discontinued due to adverse reactions. Bitter taste was reported in 8.3% of patients compared to none in the placebo group. Somnolence was reported in 0.4% of patients compared to none in the placebo group.

A total of 176 patients 5 to 12 years of age were exposed to Astelin® Nasal Spray at a dose of 1 spray each nostril twice daily in 3 placebo-controlled studies. In these studies, adverse events that occurred more frequently in patients treated with Astelin® Nasal Spray than with placebo, and that were not represented in the adult adverse event table above include rhinitis/cold symptoms (17.0% vs 9.5%), cough (11.4% vs 8.3%), conjunctivitis (5.1% vs 1.8%), and asthma (4.5% vs 4.1%).

The following events were observed infrequently ( < 2% and exceeding placebo incidence) in patients who received Astelin® Nasal Spray dosed at 1 or 2 sprays per nostril twice daily in U.S. clinical trials.

Cardiovascular: flushing, hypertension, tachycardia.

Dermatological: contact dermatitis, eczema, hair and follicle infection, furunculosis, skin laceration.

Digestive: constipation, gastroenteritis, glossitis, ulcerative stomatitis, vomiting, increased SGPT, aphthous stomatitis, diarrhea, toothache.

Metabolic and Nutritional: increased appetite.

Musculoskeletal: myalgia, temporomandibular dislocation, rheumatoid arthritis.

Neurological: hyperkinesia, hypoesthesia, vertigo.

Psychological: anxiety, depersonalization, depression, nervousness, sleep disorder, thinking abnormal.

Respiratory: bronchospasm, coughing, throat burning, laryngitis, bronchitis, dry throat, nocturnal dyspnea, nasopharyngitis, nasal congestion, pharyngolaryngeal pain, sinusitis, nasal dryness, paranasal sinus hypersecretion, post nasal drip.

Special Senses: conjunctivitis, eye abnormality, eye pain, watery eyes, taste loss.

Urogenital: albuminuria, amenorrhea, breast pain, hematuria, increased urinary frequency.

Whole Body: allergic reaction, back pain, herpes simplex, viral infection, malaise, pain in extremities, abdominal pain, pyrexia

Vasomotor Rhinitis

Adverse experience information for Astelin® Nasal Spray is derived from two placebo-controlled clinical studies which included 216 patients who received Astelin® Nasal Spray at a dose of 2 sprays per nostril twice daily for up to 28 days. The incidence of discontinuation due to adverse reactions in patients receiving Astelin® Nasal Spray was not different from vehicle placebo (2.8% vs 2.9%, respectively).

The following adverse events were reported with frequencies ≥ 2% in the Astelin® Nasal Spray treatment group and more frequently than placebo.

ADVERSE EVENT

Astelin®
Nasal Spray
n = 216

Vehicle
Placebo
n = 210

Bitter Taste

19.4

2.4

Headache

7.9

7.6

Dysesthesia

7.9

3.3

Rhinitis

5.6

2.4

Epistaxis

3.2

2.4

Sinusitis

3.2

1.9

Somnolence

3.2

1.0

Events observed infrequently ( < 2% and exceeding placebo incidence) in patients who received Astelin® Nasal Spray (2 sprays/nostril twice daily) in U.S. clinical trials in vasomotor rhinitis were similar to those observed in U.S. clinical trials in seasonal allergic rhinitis.

In controlled trials involving nasal and oral azelastine hydrochloride formulations, there were infrequent occurrences of hepatic transaminase elevations. The clinical relevance of these reports has not been established.

In addition, the following spontaneous adverse events have been reported during the marketing of Astelin® Nasal Spray and causal relationship with the drug is unknown: anaphylactoid reaction, application site irritation, atrial fibrillation, chest pain, confusion, dyspnea, facial edema, involuntary muscle contractions, palpitations, paresthesia, parosmia, pruritus, rash, disturbance or loss of sense of smell and/or taste, tolerance, urinary retention, vision abnormal and xerophthalmia.

DRUG INTERACTIONS

Concurrent use of Astelin® Nasal Spray with alcohol or other CNS depressants should be avoided because additional reductions in alertness and additional impairment of CNS performance may occur.

Cimetidine (400 mg twice daily) increased the mean Cmax and AUC of orally administered azelastine hydrochloride (4 mg twice daily) by approximately 65%. Ranitidine hydrochloride (150 mg twice daily) had no effect on azelastine pharmacokinetics.

Interaction studies investigating the cardiac effects, as measured by the corrected QT interval (QTc), of concomitantly administered oral azelastine hydrochloride and erythromycin or ketoconazole were conducted. Oral erythromycin (500 mg three times daily for seven days) had no effect on azelastine pharmacokinetics or QTc based on analyses of serial electrocardiograms. Ketoconazole (200 mg twice daily for seven days) interfered with the measurement of azelastine plasma concentrations; however, no effects on QTc were observed

PRECAUTIONS

Activities Requiring Mental Alertness: In clinical trials, the occurrence of somnolence has been reported in some patients taking Astelin® Nasal Spray; due caution should therefore be exercised when driving a car or operating potentially dangerous machinery while using Astelin® Nasal Spray. Concurrent use of Astelin® Nasal Spray with alcohol or other CNS depressants should be avoided because additional reductions in alertness and additional impairment of CNS performance may occur.

Information for Patients: Patients should be instructed to use Astelin® Nasal Spray only as prescribed. For the proper use of the nasal spray and to attain maximum improvement, the patient should read and follow carefully the accompanying patient instructions. Patients should be instructed to prime the delivery system before initial use and after storage for 3 or more days (see PATIENT INSTRUCTIONS FOR USE). Patients should also be instructed to store the bottle upright at room temperature with the pump tightly closed and out of the reach of children. In case of accidental ingestion by a young child, seek professional assistance or contact a poison control center immediately.

Patients should be advised against the concurrent use of Astelin® Nasal Spray with other antihistamines without consulting a physician. Patients who are, or may become, pregnant should be told that this product should be used in pregnancy or during lactation only if the potential benefit justifies the potential risks to the fetus or nursing infant. Patients should be advised to assess their individual responses to Astelin® Nasal Spray before engaging in any activity requiring mental alertness, such as driving a car or operating machinery. Patients should be advised that the concurrent use of Astelin® Nasal Spray with alcohol or other CNS depressants may lead to additional reductions in alertness and impairment of CNS performance and should be avoided (see : DRUG INTERACTIONS).

Carcinogenesis, Mutagenesis, Impairment of Fertility: In 2 year carcinogenicity studies in rats and mice azelastine hydrochloride did not show evidence of carcinogenicity at oral doses up to 30 mg/kg and 25 mg/kg, respectively (approximately 240 and 100 times the maximum recommended daily intranasal dose in adults and children on a mg/m2 basis).

Azelastine hydrochloride showed no genotoxic effects in the Ames test, DNA repair test, mouse lymphoma forward mutation assay, mouse micronucleus test, or chromosomal aberration test in rat bone marrow.

Reproduction and fertility studies in rats showed no effects on male or female fertility at oral doses up to 30 mg/kg (approximately 240 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis). At 68.6 mg/kg (approximately 560 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis), the duration of estrous cycles was prolonged and copulatory activity and the number of pregnancies were decreased. The numbers of corpora lutea and implantations were decreased; however, pre-implantation loss was not increased.

Pregnancy Category C: Azelastine hydrochloride has been shown to cause developmental toxicity. Treatment of mice with an oral dose of 68.6 mg/kg (approximately 280 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis) caused embryo-fetal death, malformations (cleft palate; short or absent tail; fused, absent or branched ribs), delayed ossification and decreased fetal weight. This dose also caused maternal toxicity as evidenced by decreased body weight. Neither fetal nor maternal effects occurred at a dose of 3 mg/kg (approximately 10 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis).

In rats, an oral dose of 30 mg/kg (approximately 240 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis) caused malformations (oligo-and brachydactylia), delayed ossification and skeletal variations, in the absence of maternal toxicity. At 68.6 mg/kg (approximately 560 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis) azelastine hydrochloride also caused embryo-fetal death and decreased fetal weight; however, the 68.6 mg/kg dose caused severe maternal toxicity. Neither fetal nor maternal effects occurred at a dose of 3 mg/kg (approximately 25 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis).

In rabbits, oral doses of 30 mg/kg and greater (approximately 500 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis) caused abortion, delayed ossification and decreased fetal weight; however, these doses also resulted in severe maternal toxicity. Neither fetal nor maternal effects occurred at a dose of 0.3 mg/kg (approximately 5 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis).

There are no adequate and well-controlled clinical studies in pregnant women. Astelin® Nasal Spray should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers: It is not known whether azelastine hydrochloride is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Astelin® Nasal Spray is administered to a nursing woman.

Pediatric Use: The safety and effectiveness of Astelin® Nasal Spray at a dose of 1 spray per nostril twice daily has been established for patients 5 through 11 years of age for the treatment of symptoms of seasonal allergic rhinitis. The safety of this dosage of Astelin® Nasal Spray was established in well- controlled studies of this dose in 176 patients 5 to 12 years of age treated for up to 6 weeks. The efficacy of Astelin® Nasal Spray at this dose is based on an extrapolation of the finding of efficacy in adults, on the likelihood that the disease course, pathophysiology and response to treatment are substantially similar in children compared to adults, and on supportive data from controlled clinical trials in patients 5 to 12 years of age at the dose of 1 spray per nostril twice daily. The safety and effectiveness of Astelin® Nasal Spray in patients below the age of 5 years have not been established.

Geriatric Use: Clinical studies of Astelin® Nasal Spray did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy

OVERDOSE

There have been no reported overdosages with Astelin® Nasal Spray. Acute overdosage by adults with this dosage form is unlikely to result in clinically significant adverse events, other than increased somnolence, since one bottle of Astelin® Nasal Spray contains 30 mg of azelastine hydrochloride. Clinical studies in adults with single doses of the oral formulation of azelastine hydrochloride (up to 16 mg) have not resulted in increased incidence of serious adverse events. General supportive measures should be employed if overdosage occurs. There is no known antidote to Astelin® Nasal Spray. Oral ingestion of antihistamines has the potential to cause serious adverse effects in young children. Accordingly, Astelin® Nasal Spray should be kept out of the reach of children. Oral doses of 120 mg/kg and greater (approximately 460 times the maximum recommended daily intranasal dose in adults and children on a mg/m2 basis) were lethal in mice. Responses seen prior to death were tremor, convulsions, decreased muscle tone, and salivation. In dogs, single oral doses as high as 10 mg/kg (approximately 260 times the maximum recommended daily intranasal dose in adults and children on a mg/m2 basis) were well tolerated, but single oral doses of 20 mg/kg were lethal

CLINICAL PHARMACOLOGY

Azelastine hydrochloride, a phthalazinone derivative, exhibits histamine H 1 -receptor antagonist activity in isolated tissues, animal models, and humans. Astelin® Nasal Spray is administered as a racemic mixture with no difference in pharmacologic activity noted between the enantiomers in in vitro studies. The major metabolite, desmethylazelastine, also possesses H 1 -receptor antagonist activity.

Pharmacokinetics and Metabolism

After intranasal administration, the systemic bioavailability of azelastine hydrochloride is approximately 40%. Maximum plasma concentrations (Cmax) are achieved in 2-3 hours. Based on intravenous and oral administration, the elimination half-life, steady-state volume of distribution, and plasma clearance are 22 hours, 14.5 L/kg, and 0.5 L/h/kg, respectively. Approximately 75% of an oral dose of radiolabeled azelastine hydrochloride was excreted in the feces with less than 10% as unchanged azelastine. Azelastine is oxidatively metabolized to the principal active metabolite, desmethylazelastine, by the cytochrome P450 enzyme system. The specific P450 isoforms responsible for the biotransformation of azelastine have not been identified; however, clinical interaction studies with the known CYP3A4 inhibitor erythromycin failed to demonstrate a pharmacokinetic interaction. In a multiple-dose, steady-state drug interaction study in normal volunteers, cimetidine (400 mg twice daily), a nonspecific P450 inhibitor, raised orally administered mean azelastine (4 mg twice daily) concentrations by approximately 65%.

The major active metabolite, desmethylazelastine, was not measurable (below assay limits) after single-dose intranasal administration of azelastine hydrochloride. After intranasal dosing of azelastine hydrochloride to steady-state, plasma concentrations of desmethylazelastine range from 20-50% of azelastine concentrations. When azelastine hydrochloride is administered orally, desmethylazelastine has an elimination half-life of 54 hours. Limited data indicate that the metabolite profile is similar when azelastine hydrochloride is administered via the intranasal or oral route.

In vitro studies with human plasma indicate that the plasma protein binding of azelastine and desmethylazelastine are approximately 88% and 97%, respectively.

Azelastine hydrochloride administered intranasally at doses above two sprays per nostril twice daily for 29 days resulted in greater than proportional increases in Cmax and area under the curve (AUC) for azelastine.

Studies in healthy subjects administered oral doses of azelastine hydrochloride demonstrated linear responses in Cmax and AUC.

Special Populations

Following oral administration, pharmacokinetic parameters were not influenced by age, gender, or hepatic impairment.

Based on oral, single-dose studies, renal insufficiency (creatinine clearance < 50 mL/min) resulted in a 70-75% higher Cmax and AUC compared to normal subjects. Time to maximum concentration was unchanged.

Oral azelastine has been safely administered to over 1400 asthmatic subjects, supporting the safety of administering Astelin® Nasal Spray to allergic rhinitis patients with asthma.

Pharmacodynamics

In a placebo-controlled study (95 subjects with allergic rhinitis), there was no evidence of an effect of Astelin® Nasal Spray (2 sprays per nostril twice daily for 56 days) on cardiac repolarization as represented by the corrected QT interval (QTc) of the electrocardiogram. At higher oral exposures ( ≥ 4 mg twice daily), a nonclinically significant mean change on the QTc (3-7 millisecond increase) was observed.

Interaction studies investigating the cardiac repolarization effects of concomitantly administered oral azelastine hydrochloride and erythromycin or ketoconazole were conducted. Oral erythromycin had no effect on azelastine pharmacokinetics or QTc based on analysis of serial electrocardiograms. Ketoconazole interfered with the measurement of azelastine plasma levels; however, no effects on QTc were observed (see PRECAUTIONS: DRUG INTERACTIONS).

Clinical Trials

Seasonal Allergic Rhinitis

Trials Supporting Two Sprays Per Nostril Twice Daily

U.S. placebo-controlled clinical trials of Astelin® Nasal Spray included 322 patients with seasonal allergic rhinitis who received two sprays per nostril twice a day for up to 4 weeks.

These trials included 55 pediatric patients ages 12 to 16 years. Astelin® Nasal Spray showed significant improvement compared to placebo in the two primary efficacy variables- the Total Symptom Complex (TSC) and the Major Symptom Complex (MSC).The results for the MSC are shown in Table 1 as the mean change from Baseline in the average of individual symptoms of nose blows, sneezes, runny nose/sniffles, itchy nose and watery eyes as assessed by patients on a 0-5 categorical scale.

Table 1: Summary of Primary Efficacy* Analyses for Pivotal Studies Supporting Two Sprays Per Nostril Twice Daily.

 

 

Astelin®

Placebo

Outcomes

Astelin® vs. Placebo

Mean (SD)

Difference
between
Treatments

P value

Study 26: 12 Hour AM and PM Reflective MSC

Sample Size

N=63

N=60

 

 

Baseline

11.48 (4.13)

10.84 (4.53)

 

 

Change from Baseline

-3.05 (3.51)

-1.07 (3.52)

1.98

0.0024

Study 31: 12 Hour AM and PM Reflective MSC

Sample Size

N=63

N=63

 

 

Baseline

12.50 ( 4.5)

12.18 (4.64)

 

 

Change from Baseline

-4.10 (3.46)

-2.07 (4.01)

2.03

0.0023

Study 33: 12 Hour AM and PM Reflective MSCSample Size

Sample Size

N=66

N=66

 

 

Baseline

12.04 (4.03)

11.66 (3.96)

 

 

Change from Baseline

-3.31 (3.74)

-1.96 (3.57)

1.35

0.0374

*Average of individual symptoms of nose blows, sneezes, runny nose/sniffles, itchy nose and

watery eyes as assessed by patients on a 0-5 categorical scale.

Trials Supporting One Spray Per Nostril Twice Daily

Two hundred seventy five patients with seasonal allergic rhinitis received Astelin® Nasal Spray one spray per nostril twice daily for 2 weeks in two U.S. placebo-controlled trials. The primary efficacy endpoint was the change from Baseline to Day 14 in the Total Nasal Symptom Score [TNSS] (the average of individual scores of runny nose, sneezing, itchy nose, and nasal congestion) as assessed by patients on a 0-3 categorical scale. Compared to placebo, Astelin ® Nasal Spray significantly improved the TNSS. The results are shown in Table 2.

Table 2: Summary of Primary Efficacy* Analyses for Pivotal Studies Supporting One Spray Per Nostril Twice Daily.

 

 

Astelin®

Placebo

Outcomes

Astelin® vs. Placebo

LS Mean (SD)

Difference
between
Treatments

P value

Study 419: 12 Hour AM and PM Reflective TNSS

Sample Size

N=138

N=141

 

 

Baseline

16.34 (4.222)

17.21 (4.316)

 

 

Change from Baseline

-2.69 (4.789)

-1.31 (4.285)

1.38

0.0117

Study 420: 12 Hour AM and PM Reflective TNSS

Sample Size

N=137

N=136

 

 

Baseline

16.62 (4.197)

16.84 (4.768)

 

 

Change from Baseline

-3.68 (4.163)

-2.50 (4.011)

1.18

0.0173

*Average of individual symptoms of runny nose, sneezing, itchy nose and nasal congestion as assessed by patients on a 0-3 categorical scale.

Two-week studies comparing the efficacy (and safety) of Astelin Nasal Spray two sprays per nostril twice daily versus one spray per nostril twice daily were not conducted.

Other Supporting Studies

In dose-ranging trials, administration of Astelin® Nasal Spray, two sprays per nostril twice daily, resulted in a decrease in symptoms, which reached statistical significance from saline placebo within 3 hours after initial dosing and persisted over the 12-hour dosing interval.

There were no findings on nasal examination in an 8-week study that suggested any adverse effect of azelastine on the nasal mucosa.

Vasomotor Rhinitis

Two hundred sixteen patients with vasomotor rhinitis received Astelin® Nasal Spray two sprays per nostril twice a day in two U.S. placebo controlled trials. These patients had vasomotor rhinitis for at least one year, negative skin tests to indoor and outdoor aeroallergens, negative nasal smears for eosinophils, and negative sinus X-rays, Astelin® Nasal Spray significantly improved a symptom complex comprised of rhinorrhea, post nasal drip, nasal congestion, and sneezing.

PATIENT INFORMATION

PATIENT: How To Use Instructions

FOR INTRANASAL USE ONLY

IMPORTANT: FOLLOW INSTRUCTIONS CAREFULLY TO ENSURE PROPER DOSING.

DOSING: The dosage of Astelin® Nasal Spray is 1 spray per nostril twice daily for pediatric patients (ages 5-11 years) with seasonal allergic rhinitis. For patients age 12 and older with seasonal allergic rhinitis the dosage is one or two sprays per nostril twice daily. For patients age 12 and older with nonallergic vasomotor rhinitis the dosage is two sprays per nostril twice daily. Keep your head tilted downward when spraying. Alternate sprays between nostrils. Breathe gently to avoid drawing any medication into the throat.

Follow the instructions below to use your Astelin® Nasal Spray pump.

 

TO PRIME:

  1. Remove and retain the blue spray tip dust cover and blue safety clip.
  2. Prime for initial use by putting two fingers on the shoulders of the spray pump unit and place your thumb on the bottom of the bottle. Press upward with thumb, release, and repeat until a fine mist appears (4 sprays or less). Now your pump is primed and ready to use.
  3. If the solution is delivered in a stream of liquid, it may fail to provide maximum benefit and cause some discomfort. A fine mist can be produced only by a rapid and firm pumping action.
  4. When 3 or more days have elapsed since the last use, the pump should be reprimed with 2 sprays or until a fine mist appears.

 

TO USE:

  1. Gently blow nose to clear nostrils.
  2. Keep your head tilted downward toward your toes.
  3. Place the spray tip ¼ to ½ inch into one nostril. Hold bottle vertically upright (as shown), allowing spray tip to aim toward the back of the nose. Close other nostril with finger, rapidly press once with thumb and sniff gently at the same time. You may feel a brief burning or stinging sensation after using the unit.
  4. Repeat in other nostril.
  5. For patients aged 12 and over who were instructed by their doctor to administer 2 sprays in each nostril, repeat Steps 2 and 3 for second spray, again alternating sprays between nostrils.
  6. Breathe in gently, and do not tilt head back after dosing to avoid drawing medication into the throat (where it will be tasted).

 

CAUTION: Keep bottle tightly closed and away from children. In case of accidental ingestion by a young child, seek professional assistance or contact a poison control center immediately. Do not spray in eyes.

NOTE: Keep the dust cover and safety clip on the spray pump unit when not in use. After each use and before replacing the dust cover, wipe the spray tip with a clean tissue or cloth.

FOR ASSISTANCE, CALL

1-800-598-4856

TO CLEAN:

  1. If spray nozzle becomes clogged, DO NOT ATTEMPT TO CLEAR IT USING A POINTED OBJECT. Remove the spray pump unit from the bottle.
  2. Soak only the spray pump unit in warm water. Squirt several times while holding under water.
  3. Make sure the spray pump unit is dry.
  4. Reinsert the pump into the open bottle and tighten by turning clockwise.
  5. To avoid leakage, firm pressure is required to ensure that the pump is fully threaded onto the bottle.
  6. Follow instructions for priming.

 

 

Keep bottle tightly closed and away from children

Astelin Consumer

IMPORTANT NOTE: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your health care professional. Always seek the advice of your health care professional if you have any questions about this product or your medical condition. This information is not intended as individual medical advice and does not substitute for the knowledge and judgment of your health care professional. This information does not contain any assurances that this product is safe, effective, or appropriate for you.

AZELASTINE SPRAY – NASAL

(azz-ELL-us-teen)

COMMON BRAND NAME(S): Astelin

USES: Azelastine is used to relieve nasal symptoms such as runny/itching/stuffy nose, sneezing, and post-nasal drip caused by seasonal allergies and other allergic conditions. This medication is an antihistamine. It works by blocking certain natural substances called histamines that are responsible for allergic symptoms.

HOW TO USE: Read the Patient Information Leaflet provided by your pharmacist before you start using azelastine and each time you get a refill. Follow the instructions on how to properly use this medication. If you have any questions regarding the information, consult your doctor or pharmacist.

Follow the instructions for properly priming the spray pump before using the bottle for the first time and if you have not used the medication for 3 or more days. Avoid spraying in your eyes or mouth.

Azelastine is for use in your nose and is available in different strengths. Use 1 or 2 sprays in both nostrils, usually once or twice a day as directed by your doctor. The dosage is based on your condition, the product you are using, and your response to treatment.

Use this medication regularly in order to get the most benefit from it. Remember to use it at the same time(s) each day. This medicine usually begins working within 3 hours of use.

Astelin Consumer (continued)

SIDE EFFECTS: A bitter taste in the mouth, drowsiness, a burning feeling inside the nose, sneezing fits, nausea, weight gain, muscle aches, and red eyes may occur. Strange feelings on the skin (e.g., pins and needles, crawling sensation) may also occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

The bitter taste can be reduced by sniffing gently through your nose after each spray, rather than breathing in through your nose so deeply that the medication goes to the back of your throat and gets into your mouth.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

A very serious allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of a serious allergic reaction may include: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US –

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada – Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

PRECAUTIONS: Before using azelastine, tell your doctor or pharmacist if you are allergic to it; or to the preservative benzalkonium chloride; or if you have any other allergies.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney problems.

This drug may make you drowsy. Do not drive, use machinery, or do any activity that requires alertness until you are sure you can perform such activities safely. Limit alcoholic beverages.

This medication should be used only when clearly needed during pregnancy. Discuss the risks and benefits with your doctor.

It is not known whether this drug passes into breast milk. Consult your doctor before breast-feeding

Astelin Consumer (continued)

DRUG INTERACTIONS: Your healthcare professionals (e.g., doctor or pharmacist) may already be aware of any possible drug interactions and may be monitoring you for it. Do not start, stop or change the dosage of any medicine before checking with them first.

Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use, especially of: cimetidine.

Tell your doctor or pharmacist if you also take drugs that cause drowsiness such as: other antihistamines (e.g., diphenhydramine), anti-anxiety drugs (e.g., diazepam), anti-seizure drugs (e.g., phenobarbital), medicine for sleep (e.g., zolpidem), muscle relaxants, narcotic pain relievers (e.g., codeine), psychiatric medicines (e.g., phenothiazines such as chlorpromazine or tricyclics such as amitriptyline), tranquilizers.

Check the labels on all your medicines (e.g., cough-and-cold products) because they may contain drowsiness-causing ingredients. Ask your pharmacist about the safe use of those products.

This document does not contain all possible interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

OVERDOSE: If overdose is suspected, contact your local poison control center or emergency room immediately. US residents can call the US national poison hotline at 1-800-222-1222. Canadian residents should call their local poison control center directly.

NOTES: Do not share this medication with others.

MISSED DOSE: If you miss a dose, use it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

STORAGE: Store at controlled room temperature between 68-77 degrees F (20-25 degrees C) away from light and moisture. Keep the bottle upright with the pump tightly closed. Protect from freezing. Do not store in the bathroom. Keep all medicines away from children and pets.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product

Astelin Patient Information Including Side Effects

Brand Names: Astelin, Astepro

Generic Name: azelastine nasal (Pronunciation: a ZEL uh steen)

  • What is azelastine nasal (Astelin)?
  • What are the possible side effects of azelastine nasal (Astelin)?
  • What is the most important information I should know about azelastine nasal (Astelin)?
  • What should I discuss with my healthcare provider before using azelastine nasal (Astelin)?
  • How should I use azelastine nasal (Astelin)?
  • What happens if I miss a dose (Astelin)?
  • What happens if I overdose (Astelin)?
  • What should I avoid while taking azelastine nasal (Astelin)?
  • What other drugs will affect azelastine nasal (Astelin)?
  • Where can I get more information?

What is azelastine nasal (Astelin)?

Azelastine is an antihistamine. It blocks the effects of the chemical histamine in your body.

Azelastine prevents sneezing, itching, runny nose, and other nasal symptoms of allergies.

Azelastine nasal may also be used for other purposes not listed in this medication guide.

Astelin Nasal

 

Prev 1 Next

What are the possible side effects of azelastine nasal (Astelin)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Stop using azelastine and call your doctor at once if you have any of these serious side effects:

  • bronchospasm (shortness of breath, tightness in chest, wheezing); or
  • fast or uneven heartbeats.

Less serious side effects may include:

  • a bitter taste in your mouth;
  • headache;
  • drowsiness or dizziness;
  • dry mouth, sore throat;
  • burning in your nose;
  • weight gain;
  • nausea;
  • nosebleed;
  • cough, sneezing, runny nose, cold symptoms; or
  • eye redness.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is the most important information I should know about azelastine nasal (Astelin)?

Azelastine can cause side effects that may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be awake and alert.

Avoid drinking alcohol. It can increase drowsiness and dizziness caused by azelastine.

Before using azelastine nasal, tell your doctor if you regularly use other medicines that make you sleepy (such as cold or allergy medicine, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused by azelastine nasal

Astelin Patient Information including How Should I Take

In this Article

  • What is azelastine nasal (Astelin)?
  • What are the possible side effects of azelastine nasal (Astelin)?
  • What is the most important information I should know about azelastine nasal (Astelin)?
  • What should I discuss with my healthcare provider before using azelastine nasal (Astelin)?
  • How should I use azelastine nasal (Astelin)?
  • What happens if I miss a dose (Astelin)?
  • What happens if I overdose (Astelin)?
  • What should I avoid while taking azelastine nasal (Astelin)?
  • What other drugs will affect azelastine nasal (Astelin)?
  • Where can I get more information?

 

What should I discuss with my healthcare provider before using azelastine nasal (Astelin)?

You should not use this medication if you are allergic to azelastine.

Before using azelastine nasal, tell your doctor if you have any other medical conditions or if you take other prescription or over-the-counter medications.

FDA pregnancy category C. It is not known whether azelastine nasal is harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment.

It is not known whether azelastine passes into breast milk or if it could harm a nursing baby. Do not use azelastine nasal without telling your doctor if you are breast-feeding a baby.

Azelastine nasal should not be given to a child younger than 5 years old.

How should I use azelastine nasal (Astelin)?

Use azelastine exactly as it was prescribed for you. Do not use it in larger doses or for longer than recommended by your doctor. Follow the directions on your prescription label.

To use the azelastine nasal spray:

  • Gently blow your nose before using the nasal spray.
  • The first time you use a new bottle, screw the pump device onto the bottle. Prime the unit by pumping 4 sprays into the air, away from your face, until a fine mist appears. Prime the spray pump any time it has been longer than 3 days since you last used it.
  • Insert the spray tip into your nostril, pointing it straight up into your nose. Press your other nostril closed with your finger and keep your head upright. Pump the spray and gently inhale at the same time.
  • Use only the number of sprays prescribed by your doctor.
  • Clean the pump nozzle with a clean, damp tissue and recap it.

Try not to sneeze or blow your nose just after using the spray.

Talk with your doctor if your symptoms do not improve or if they get worse.

Store this medication at room temperature in an upright position, away from moisture and heat. Keep the dust cover on the spray nozzle when not in use

Astelin Patient Information including If I Miss a Dose

In this Article

  • What is azelastine nasal (Astelin)?
  • What are the possible side effects of azelastine nasal (Astelin)?
  • What is the most important information I should know about azelastine nasal (Astelin)?
  • What should I discuss with my healthcare provider before using azelastine nasal (Astelin)?
  • How should I use azelastine nasal (Astelin)?
  • What happens if I miss a dose (Astelin)?
  • What happens if I overdose (Astelin)?
  • What should I avoid while taking azelastine nasal (Astelin)?
  • What other drugs will affect azelastine nasal (Astelin)?
  • Where can I get more information?

 

What happens if I miss a dose (Astelin)?

Use the medication as soon as you remember. If it is almost time for the next dose, skip the missed dose and wait until your next regularly scheduled dose. Do not use extra medicine to make up the missed dose.

What happens if I overdose (Astelin)?

Seek emergency medical attention if you think you have used too much of this medicine.

Overdose symptoms may include extreme sleepiness.

What should I avoid while taking azelastine nasal (Astelin)?

Azelastine can cause side effects that may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be awake and alert.

Avoid drinking alcohol. It can increase drowsiness and dizziness caused by azelastine.

What other drugs will affect azelastine nasal (Astelin)?

Before using azelastine nasal, tell your doctor if you regularly use other medicines that make you sleepy (such as cold or allergy medicine, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused by azelastine nasal.

Also tell your doctor if you are using cimetidine (Tagamet).

There may be other drugs that can interact with azelastine. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

Where can I get more information?

Your pharmacist can provide more information about azelastine nasal.


Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. (‘Multum’) is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum’s drug information does not endorse drugs, diagnose patients or recommend therapy. Multum’s drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

 

 

Leave a Reply